Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896 | 0.98 | ALDH1A1 (0.59) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Hydrochloric Acid SCHEMBL28253846 | 0.96 | ALDH1A1 (0.57) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL11039497 | 0.96 | ALDH1A1 (0.57) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Water SCHEMBL316720 | 0.96 | ALDH1A1 (0.57) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Ammonia Solution, Strong SCHEMBL27831351 | 0.96 | ALDH1A1 (0.57) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Purine SCHEMBL5315439 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Pyrimidine SCHEMBL29199390 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Imidazole SCHEMBL28111160 | 0.83 | ALDH1A1 (0.45) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| SCHEMBL16752071 | 0.82 | KDM4E (0.44) | ALDH1A1KDM4ECDK2RXFP1PAK1 | |
| Mercaptopurine Anhydrous SCHEMBL5534039 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KDM4ECDK2RXFP1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200262830-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-08-20 | — | — | US | disclosed |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3218372-B1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-10570125-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| EP-2403852-A1 | 3H-IMIDAZO [4, 5 -C]PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090275611-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| EP-2007707-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007118041-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 1695/4885KDM4E 3926/4885CDK2 993/4885 |
| US-20200262830-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | ALDH1A1 3033/4885KDM4E 831/4885CDK2 1024/4885 |
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | ALDH1A1 228/4885KDM4E 2387/4885CDK2 703/4885 |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | ALDH1A1 2937/4885KDM4E 872/4885CDK2 923/4885 |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | ALDH1A1 2937/4885KDM4E 872/4885CDK2 923/4885 |
| US-10570125-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | ALDH1A1 2937/4885KDM4E 872/4885CDK2 923/4885 |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR1, SSTR3 | ALDH1A1 2546/4885KDM4E 1147/4885CDK2 2219/4885 |
| US-20090275611-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, OPRL1 | ALDH1A1 3085/4885KDM4E 3287/4885CDK2 670/4885 |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | ALDH1A1 2937/4885KDM4E 872/4885CDK2 923/4885 |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | ALDH1A1 3117/4885KDM4E 2536/4885CDK2 3509/4885 |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | ALDH1A1 3033/4885KDM4E 831/4885CDK2 1024/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | ALDH1A1 1761/4885KDM4E 2615/4885CDK2 1543/4885 |
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | ALDH1A1 2937/4885KDM4E 872/4885CDK2 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.